Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2210-2216

  Rajkumar, S Vincent ^a   Mesa, Ruben A ^a   Fonseca, Rafael ^a   Schroeder, Georgene ^a   Plevak, Matthew F ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Lust, John A ^a   Witzig, Thomas E ^a   Gertz, Morie A ^a   Kyle, Robert A ^a   Russell, Stephen J ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; BETA 2 MICROGLOBULIN;

ADVANCED CANCER; AMYLOIDOSIS; ANGIOGENESIS; ANTIGEN DETECTION; ARTICLE; BONE MARROW CELL; CANCER STAGING; CANCER SURVIVAL; CELL LABELING; CONTROLLED STUDY; CORRELATION ANALYSIS; DENSITY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULARIZATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RELAPSE; BONE MARROW; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PARAPROTEINEMIA; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULARIZATION;

AMYLOIDOSIS; ANTIGENS, CD34; BETA 2-MICROGLOBULIN; BONE MARROW; CASE-CONTROL STUDIES; COMPARATIVE STUDY; DISEASE PROGRESSION; HUMAN; IMMUNOENZYME TECHNIQUES; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PARAPROTEINEMIAS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE; TREATMENT OUTCOME; HUMANS;

EID: 0035992360     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tumor angiogenesis: Therapeutic implications
2. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
3. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
4. Tumoral vascularity as a prognostic factor in cancer
5. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
6. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies
7. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
8. "Benign" monoclonal gammopathy-after 20 to 35 years of follow-up
9. Smoldering multiple myeloma
10. Bone marrow angiogenesis and progression in multiple myeloma
11. Prognostic value of bone marrow angiogenesis in multiple myeloma
12. A review of angiogenesis and anti-angiogenic therapy with thalidomide in multiple myeloma
13. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density. Chalkley count, and computer image analysis
14. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies
15. Plasma cell labeling index and β 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
16. Nonparametric estimation from incomplete observations
17. Regression models and life tables
18. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies
19. A long-term study of prognosis of monoclonal gammopathy of undetermined significance
20. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
21. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
22. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis
23. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
24. Bone marrow (BM) angiogenesis in multiple myeloma (MM): Effect of therapy and prognostic value
25. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy
26. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities in multiple myeloma: An Eastern Cooperative Oncology Group Study
27. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum β2-microglobulin levels in patients with multiple myeloma
28. Control of myeloma with the anti-angiogenic agent endostatin
29. Vascular endothelial growth factor: A key mediator of neoangiogenesis. A review
30. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells
31. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
32. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
33. Angiogenesis in myeloma: Expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells
34. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
35. Expression of VEGF and its receptors by myeloma cells
36. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
37. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma
38. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma
39. Bone marrow angiogenesis in patients with active multiple myeloma
40. Antitumor activity of thalidomide in refractory multiple myeloma
41. Current status of thalidomide in the treatment of cancer
42. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy
43. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma